Metagenomi, Inc. (MGX)
NASDAQ:MGX
Want to see MGX full AI Analyst Report?
Top Page
Metagenomi, Inc.
(NASDAQ:MGX)
Select Model
Select Model
Rating:44Neutral
Price Target:
$1.00
▼(-32.43% Downside)
Action:Reiterated
Date:06/10/26
The score is held down mainly by weak financial performance, driven by severe and persistent losses, negative margins, and heavy cash burn that implies continued external funding needs. Technicals also point to a clear downtrend with negative momentum, despite oversold readings. Valuation provides limited support because the negative P/E reflects unprofitability and there is no dividend yield.
Positive Factors
Low leverage / supportive balance sheet
Sustained low leverage (debt/equity ~0.28) gives the company financial flexibility to fund R&D and clinical programs without heavy interest burden. This durable balance-sheet characteristic reduces refinancing risk and preserves optionality while programs mature over the next 2-6+ months.
Negative Factors
Severe and persistent unprofitability
Extremely negative operating and net margins indicate structural unprofitability that will persist absent major commercialization or partner-funded milestones. Such deep losses erode equity value, compress returns on invested capital, and necessitate strategic prioritization of programs under constrained economics.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / supportive balance sheet
Sustained low leverage (debt/equity ~0.28) gives the company financial flexibility to fund R&D and clinical programs without heavy interest burden. This durable balance-sheet characteristic reduces refinancing risk and preserves optionality while programs mature over the next 2-6+ months.
Read all positive factors
Metagenomi, Inc. (MGX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$45.18M
Dividend YieldN/A
Average Volume (3M)883.52K
Price to Earnings (P/E)―
Beta (1Y)1.04
Revenue Growth-50.66%
EPS Growth-9.30%
CountryUS
Employees202
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.30
Shares Outstanding37,646,860
10 Day Avg. Volume1,405,864
30 Day Avg. Volume883,524
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)0.38
Price to Sales (P/S)2.39
P/FCF Ratio-0.67
Enterprise Value/Market Cap1.29
Enterprise Value/Revenue2.61
Enterprise Value/Gross Profit-20.82
Enterprise Value/Ebitda-0.72
Forecast
1Y Price Target
$8.00Price Target Upside440.54% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-2.12
Revenue Forecast (FY)$12.15M
Metagenomi, Inc. Business Overview & Revenue Model
Company Description
Metagenomi, Inc. operates as a biotechnology company focused on gene editing, committed to developing therapeutic solutions for patients. The company utilizes a distinctive genome editing toolkit, sourced from metagenomics, for its development eff...
How the Company Makes Money
Metagenomi’s revenue model is primarily based on partnering and licensing its gene-editing platform and related intellectual property to other life-science companies. Key revenue streams typically include (1) upfront payments received when enterin...
Metagenomi, Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
56
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 22.33M | 25.21M | 52.30M | 44.76M | 17.20M | 243.00K |
| Gross Profit | -2.80M | 19.89M | 52.30M | -49.65M | 15.47M | -144.00K |
| EBITDA | -80.80M | -82.61M | -78.16M | -56.02M | -39.19M | -20.75M |
| Net Income | -85.89M | -87.87M | -78.06M | -68.25M | -43.59M | -21.44M |
Balance Sheet | ||||||
| Total Assets | 196.95M | 221.10M | 324.60M | 364.84M | 414.49M | 141.99M |
| Cash, Cash Equivalents and Short-Term Investments | 140.16M | 160.80M | 248.31M | 271.18M | 362.13M | 108.15M |
| Total Debt | 39.19M | 40.66M | 45.78M | 48.23M | 18.57M | 48.93M |
| Total Liabilities | 59.17M | 62.51M | 89.74M | 149.67M | 488.91M | 174.54M |
| Stockholders Equity | 137.78M | 158.60M | 234.86M | 215.17M | -74.43M | -32.54M |
Cash Flow | ||||||
| Free Cash Flow | -87.54M | -89.47M | -112.19M | -101.22M | 15.75M | 21.35M |
| Operating Cash Flow | -87.22M | -88.89M | -109.07M | -91.41M | 29.72M | 24.26M |
| Investing Cash Flow | 82.79M | 103.53M | -88.16M | 45.73M | -122.20M | -74.32M |
| Financing Cash Flow | -306.00K | -356.00K | 84.01M | 1.01M | 239.59M | 39.92M |
Metagenomi, Inc. Technical Analysis
Negative
1.48
Price Trends
1.35
Negative
1.42
Negative
1.74
Negative
Market Momentum
-0.05
Positive
39.20
Neutral
20.44
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MGX, the sentiment is Negative. The current price of 1.48 is above the 20-day moving average (MA) of 1.28, above the 50-day MA of 1.35, and below the 200-day MA of 1.74, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 39.20 is Neutral, neither overbought nor oversold. The STOCH value of 20.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MGX.
Metagenomi, Inc. Risk Analysis
Metagenomi, Inc. disclosed 77 risk factors in its most recent earnings report. Metagenomi, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Metagenomi, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | $193.43M | -4.10 | -220.75% | ― | ― | 38.59% | |
54 Neutral | $158.79M | 1.44 | 55.29% | ― | -100.00% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $90.73M | ― | 25.68% | ― | -88.41% | 76.14% | |
45 Neutral | $58.06M | -1.50 | -59.95% | ― | ― | -24.56% | |
44 Neutral | $45.18M | -0.53 | -51.23% | ― | -50.66% | -9.30% | |
40 Underperform | $17.07M | -0.30 | -208.23% | ― | -100.00% | 26.30% |
* Healthcare Sector Average
MGX
Metagenomi, Inc.
1.20
-0.25
-17.24%
ORMP
Oramed Pharm
3.88
1.89
95.47%
IMUX
Immunic
14.20
7.00
97.22%
ATRA
Atara Biotherapeutics
10.07
2.13
26.83%
HOWL
Werewolf Therapeutics
0.35
-0.84
-70.50%
CNTX
Context Therapeutics
0.63
0.06
10.31%
Metagenomi, Inc. Corporate Events
Executive/Board ChangesShareholder Meetings
Metagenomi Announces Board Changes and Shareholder Meeting Results
Positive
Jun 10, 2026
On June 9, 2026, Metagenomi Therapeutics, Inc. announced that board member Brian C. Thomas, Ph.D. resigned from the board effective the same day, with the company emphasizing that his departure did not stem from any disagreement over its operation...
Business Operations and StrategyExecutive/Board ChangesFinancial Disclosures
Metagenomi Highlights Q1 Progress on MGX-001 Gene Therapy
Positive
May 11, 2026
Metagenomi Therapeutics reported first quarter 2026 results on May 11, 2026, highlighting progress on its MGX-001 hemophilia A program and platform technologies while maintaining a cash position of $140.2 million, which it expects will fund operat...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.